Antal Zemplényi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Antal Zemplényi has a total of 253 co-authors. Here are the top co-authors by number of shared publications:
- Zoltán Kaló
Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary
13 shared publications - Imre Boncz
Institute of Nursing Sciences, Basic Health Sciences and Health Visiting, Faculty of Health Sciences, University of Pécs, Pécs 7622, Hungary, Hungary
6 shared publications - Sándor Kovács
Center for Health Technology Assessment and Pharmacoeconomic Research, Faculty of Pharmacy, University of Pécs, H-7624 Pécs, Hungary
6 shared publications - Bertalan Németh
Syreon Research Institute, Budapest, Hungary
4 shared publications - István Kiss
Department of Public Health Medicine, Medical School, University of Pécs, 7624 Pécs, Hungary
4 shared publications Zoltán Kaló
Center for Health Technology Assessment and Pharmacoeconomics Research, Faculty of Pharmacy, University of Pécs, Pécs, Hungary
4 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Springer Nature in PharmacoEconomics - Open
- p. 1-22
Methodological Divergence in Oncology HTA: Implications for International Harmonization and the Handling of Uncertainty
- 27 October 2026
- Published by Springer Nature in PharmacoEconomics - Open
- p. 1-22
Open AccessMethodological Divergence in Oncology HTA: Implications for International Harmonization and the Handling of Uncertainty
- 9 August 2026
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 26 (7) , 851-860
From general-purpose models to purpose-built artificial intelligence systems for health economic modeling
1. 1.1. Artificial intelligence (AI) capabilities advanced markedly in recent years, with large language models (LLMs) demonstrating proficiency across a range of knowledge-intensive tasks. Benchma...
- 9 August 2026
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 26 (7) , 851-860
From general-purpose models to purpose-built artificial intelligence systems for health economic modeling
1. 1.1. Artificial intelligence (AI) capabilities advanced markedly in recent years, with large language models (LLMs) demonstrating proficiency across a range of knowledge-intensive tasks. Benchma...
- Open Access
- 25 July 2026
- Published by Springer Nature in BMC Palliative Care
- Vol. 25 (1)
Added value of a specialized mobile palliative care team compared to the usual care in the primary care setting of Croatia: a 3-month prospective cohort study
Background: Croatia has been implementing a Mobile multidisciplinary specialist palliative care team (MMSPCT), a home-based specialized palliative care service at the primary healthcare level since 2011. This study aimed to evaluate whether a MMSPCT performs better than usual care, in terms of health/well-being, experience with care, and cost outcomes. Methods: A 3-month prospective cohort study was performed during 2017–2019. Two cohorts were compared: MMSPCT vs. usual care cohort. Sample size was based on the literature data, ranging 150–200 patients per group. A SELFIE questionnaire with selected standardised instruments was used to assess health/well-being, experience with care, and cost (on four categories: drugs, medical devices, hospitalisation for acute and chronic care), at the beginning (T0), after 1 (T1), and after 3 months (T2). Propensity score weighting using subclassification method was used to reduce selection bias by grouping exposed and control group patients into four subclasses based on similar propensity scores. The average treatment effect on the treated (ATT) was estimated using linear models with propensity score weighing and clustering based on the subclasses of propensity scores. Cost outcome variables were analysed using hurdle models due to zero-inflation in the data. Results: 410 palliative care patients were included, 220 in MMSPCT and 190 in usual care cohort; 94 patients (42.7%) vs. 124 (65.3%) completed the study at 3-months follow-up. Baseline characteristics: age, gender and number of health conditions were balanced after propensity score weighting, but not living situation, education level, marital status and smoking. After 1 and 3 months, MMSPCT patients scored significantly better on person centeredness: 0.69 (3.83%) and 1.87 (10.39%) units higher score and compassionate care: 3.33 (2.78%) and 6.14 (5.12%) points more. After 3 months, they scored significantly better on physical (4.1 points more) and emotional functioning (5.18 points more) and had significantly lower measured healthcare costs. More MMSPCT patients died at their preferred place of death (48% vs. 23%). Conclusion: MMSPCT at primary care level may offer added value to palliative patients in Croatia and may result in a net saving in measured healthcare costs. Further clinical research is needed with a longer follow-up period and children’s cohorts.
- 25 July 2026
- Published by Springer Nature in BMC Palliative Care
- Vol. 25 (1)
Open AccessAdded value of a specialized mobile palliative care team compared to the usual care in the primary care setting of Croatia: a 3-month prospective cohort study
Background: Croatia has been implementing a Mobile multidisciplinary specialist palliative care team (MMSPCT), a home-based specialized palliative care service at the primary healthcare level since 2011. This study aimed to evaluate whether a MMSPCT performs better than usual care, in terms of health/well-being, experience with care, and cost outcomes. Methods: A 3-month prospective cohort study was performed during 2017–2019. Two cohorts were compared: MMSPCT vs. usual care cohort. Sample size was based on the literature data, ranging 150–200 patients per group. A SELFIE questionnaire with selected standardised instruments was used to assess health/well-being, experience with care, and cost (on four categories: drugs, medical devices, hospitalisation for acute and chronic care), at the beginning (T0), after 1 (T1), and after 3 months (T2). Propensity score weighting using subclassification method was used to reduce selection bias by grouping exposed and control group patients into four subclasses based on similar propensity scores. The average treatment effect on the treated (ATT) was estimated using linear models with propensity score weighing and clustering based on the subclasses of propensity scores. Cost outcome variables were analysed using hurdle models due to zero-inflation in the data. Results: 410 palliative care patients were included, 220 in MMSPCT and 190 in usual care cohort; 94 patients (42.7%) vs. 124 (65.3%) completed the study at 3-months follow-up. Baseline characteristics: age, gender and number of health conditions were balanced after propensity score weighting, but not living situation, education level, marital status and smoking. After 1 and 3 months, MMSPCT patients scored significantly better on person centeredness: 0.69 (3.83%) and 1.87 (10.39%) units higher score and compassionate care: 3.33 (2.78%) and 6.14 (5.12%) points more. After 3 months, they scored significantly better on physical (4.1 points more) and emotional functioning (5.18 points more) and had significantly lower measured healthcare costs. More MMSPCT patients died at their preferred place of death (48% vs. 23%). Conclusion: MMSPCT at primary care level may offer added value to palliative patients in Croatia and may result in a net saving in measured healthcare costs. Further clinical research is needed with a longer follow-up period and children’s cohorts.
- Open Access
Changes in the Characteristics of Kidney Cancer Detection During the COVID-19 Pandemic
Background/objectives: The COVID-19 pandemic affected cancer care globally. Our objective was to analyze the demographic and clinical characteristics of kidney cancer (KC) patients between the pre-COVID-19 and COVID-19 periods. We also aimed to assess how KC was discovered—incidentally or symptomatically—and identify factors predicting the mode of discovery and advanced-stage disease. Methods: This retrospective study analyzed data from 400 patients aged 18 years or older diagnosed with kidney cancer (KC) at a large regional Hungarian clinical center during two time periods: the pre-COVID-19 period (1 January 2019 to 15 March 2020) and the COVID-19 period (16 March 2020 to 13 May 2021). Demographic and clinical information, including the mode of cancer discovery, was collected for all patients. Results: During the pandemic, monthly kidney cancer diagnoses declined by 10.3%. The proportion of female patients rose significantly from 31.9% to 42.9% (p = 0.023). Incidental tumor detection decreased from 82.4% to 72.4% (p = 0.018), while symptomatic presentation increased from 14.2% to 19.4%, although not significantly (p = 0.166). Non-incidental detection was associated with a 3.42-fold increase in odds of advanced cancer pre-pandemic and a 2.03-fold increase during the pandemic. Symptomatic presentation raised these odds by 4.51 and 2.76 times, respectively. Conclusions: Our study revealed changes in kidney cancer detection during the pandemic, including a rise in the proportion of female patients and a decline in case numbers, likely due to reduced incidental findings. Non-incidental discovery and symptom presence remained predictors of advanced-stage disease, although the odds were lower. Various factors—such as changes in healthcare access and gender-related differences in health-seeking behavior—may possibly explain these changes. Our findings support the critical role of incidental detection in high-risk populations.
Open AccessChanges in the Characteristics of Kidney Cancer Detection During the COVID-19 Pandemic
Background/objectives: The COVID-19 pandemic affected cancer care globally. Our objective was to analyze the demographic and clinical characteristics of kidney cancer (KC) patients between the pre-COVID-19 and COVID-19 periods. We also aimed to assess how KC was discovered—incidentally or symptomatically—and identify factors predicting the mode of discovery and advanced-stage disease. Methods: This retrospective study analyzed data from 400 patients aged 18 years or older diagnosed with kidney cancer (KC) at a large regional Hungarian clinical center during two time periods: the pre-COVID-19 period (1 January 2019 to 15 March 2020) and the COVID-19 period (16 March 2020 to 13 May 2021). Demographic and clinical information, including the mode of cancer discovery, was collected for all patients. Results: During the pandemic, monthly kidney cancer diagnoses declined by 10.3%. The proportion of female patients rose significantly from 31.9% to 42.9% (p = 0.023). Incidental tumor detection decreased from 82.4% to 72.4% (p = 0.018), while symptomatic presentation increased from 14.2% to 19.4%, although not significantly (p = 0.166). Non-incidental detection was associated with a 3.42-fold increase in odds of advanced cancer pre-pandemic and a 2.03-fold increase during the pandemic. Symptomatic presentation raised these odds by 4.51 and 2.76 times, respectively. Conclusions: Our study revealed changes in kidney cancer detection during the pandemic, including a rise in the proportion of female patients and a decline in case numbers, likely due to reduced incidental findings. Non-incidental discovery and symptom presence remained predictors of advanced-stage disease, although the odds were lower. Various factors—such as changes in healthcare access and gender-related differences in health-seeking behavior—may possibly explain these changes. Our findings support the critical role of incidental detection in high-risk populations.
- Open Access
Shorter Time to Biopsy of Patients with Head and Neck Squamous Cell Carcinoma During the COVID-19 Pandemic in Hungary
Background/objectives: The goal of this investigation was to compare the time to biopsy (TBI) and time to treatment (TTI) for head and neck squamous cell carcinoma (HNSCC) patients before and during the COVID-19 pandemic and to examine the effect of demographic and clinical characteristics on these intervals. Methods: Our retrospective study at a large regional Hungarian cancer center analyzed data from patients aged 18 or older diagnosed with HNSCC between 1 January 2017 and 15 March 2020 (pre-COVID-19 period) and 16 March 2020 to 13 May 2021 (COVID-19 period). We calculated the time from initial physician contact to biopsy (TBI) and from biopsy to treatment initiation (TTI) and performed descriptive and exploratory statistical analyses. Results: The median TBI decreased significantly (6 vs. 3 days; p = 0.008), while the median TTI was not affected significantly (28 vs. 29 days; p = 0.972) pre-pandemic and during the pandemic, respectively. Residence in a village was linked to a significant reduction in median TBI during the pandemic (p = 0.000), coinciding with a higher proportion of rural patients diagnosed with oral cavity/oropharyngeal cancers during the pandemic (50.3% pre-pandemic vs. 67.4% during pandemic, p = 0.044). Median TTI decreased significantly during the pandemic for patients with laryngeal tumors (27.5 vs. 18.5 days; p = 0.012). Conclusions: Our study, one of a few from this region, provides insights into HNSCC patient waiting times. Improvement in TBI likely resulted from the availability of telemedicine, reduced diagnostic demands from non-cancer patients, and an increased incidence of oral cavity/oropharyngeal cancer among rural patients.
Open AccessShorter Time to Biopsy of Patients with Head and Neck Squamous Cell Carcinoma During the COVID-19 Pandemic in Hungary
Background/objectives: The goal of this investigation was to compare the time to biopsy (TBI) and time to treatment (TTI) for head and neck squamous cell carcinoma (HNSCC) patients before and during the COVID-19 pandemic and to examine the effect of demographic and clinical characteristics on these intervals. Methods: Our retrospective study at a large regional Hungarian cancer center analyzed data from patients aged 18 or older diagnosed with HNSCC between 1 January 2017 and 15 March 2020 (pre-COVID-19 period) and 16 March 2020 to 13 May 2021 (COVID-19 period). We calculated the time from initial physician contact to biopsy (TBI) and from biopsy to treatment initiation (TTI) and performed descriptive and exploratory statistical analyses. Results: The median TBI decreased significantly (6 vs. 3 days; p = 0.008), while the median TTI was not affected significantly (28 vs. 29 days; p = 0.972) pre-pandemic and during the pandemic, respectively. Residence in a village was linked to a significant reduction in median TBI during the pandemic (p = 0.000), coinciding with a higher proportion of rural patients diagnosed with oral cavity/oropharyngeal cancers during the pandemic (50.3% pre-pandemic vs. 67.4% during pandemic, p = 0.044). Median TTI decreased significantly during the pandemic for patients with laryngeal tumors (27.5 vs. 18.5 days; p = 0.012). Conclusions: Our study, one of a few from this region, provides insights into HNSCC patient waiting times. Improvement in TBI likely resulted from the availability of telemedicine, reduced diagnostic demands from non-cancer patients, and an increased incidence of oral cavity/oropharyngeal cancer among rural patients.
- Open Access
Changes in Time to Initial Physician Contact and Cancer Stage Distribution during the COVID-19 Pandemic in Patients with Head and Neck Squamous Cell Carcinoma at a Large Hungarian Cancer Center
The aim of our study was to compare the characteristics and time to initial physician contact in patients with head and neck squamous cell carcinoma (HNSCC) before and during the COVID-19 pandemic at a large Hungarian cancer center. This was a retrospective study of patients 18 years or older presenting at the regional cancer center of Pécs Clinical Center with HNSCC between 1 January 2017, and 15 March 2020 (the pre-COVID-19 period) and between 16 March 2020, and 13 May 2021 (the COVID-19 period). Demographic and clinical data were collected, and the time between initial symptom onset and initial physician contact (TTP) was determined. Descriptive and exploratory statistical analyses were performed. On average, the number of patients diagnosed with HNSCC per month during the pandemic decreased by 12.4% compared with the pre-COVID-19 period. There was a significant increase in stage I and stage II cancers (from 15.9% to 20.3% and from 12.2% to 13.8%, respectively; p < 0.001); a decrease in stage III and IVa,c cancers; and a significant increase in stage IVb cancers (from 6% to 19.9%; p < 0.001) during the pandemic. The median TTP increased during the pandemic from 43 to 61 days (p = 0.032). To our knowledge, this is the first study investigating the effect of COVID-19 on patients with HNSCC in the Central–Eastern European region. We found a bidirectional shift in cancer stages and increased TTP during the pandemic. Our findings highlight the necessity for more nuanced analyses of the effects of COVID-19.
Open AccessChanges in Time to Initial Physician Contact and Cancer Stage Distribution during the COVID-19 Pandemic in Patients with Head and Neck Squamous Cell Carcinoma at a Large Hungarian Cancer Center
The aim of our study was to compare the characteristics and time to initial physician contact in patients with head and neck squamous cell carcinoma (HNSCC) before and during the COVID-19 pandemic at a large Hungarian cancer center. This was a retrospective study of patients 18 years or older presenting at the regional cancer center of Pécs Clinical Center with HNSCC between 1 January 2017, and 15 March 2020 (the pre-COVID-19 period) and between 16 March 2020, and 13 May 2021 (the COVID-19 period). Demographic and clinical data were collected, and the time between initial symptom onset and initial physician contact (TTP) was determined. Descriptive and exploratory statistical analyses were performed. On average, the number of patients diagnosed with HNSCC per month during the pandemic decreased by 12.4% compared with the pre-COVID-19 period. There was a significant increase in stage I and stage II cancers (from 15.9% to 20.3% and from 12.2% to 13.8%, respectively; p < 0.001); a decrease in stage III and IVa,c cancers; and a significant increase in stage IVb cancers (from 6% to 19.9%; p < 0.001) during the pandemic. The median TTP increased during the pandemic from 43 to 61 days (p = 0.032). To our knowledge, this is the first study investigating the effect of COVID-19 on patients with HNSCC in the Central–Eastern European region. We found a bidirectional shift in cancer stages and increased TTP during the pandemic. Our findings highlight the necessity for more nuanced analyses of the effects of COVID-19.
- Open Access
- 22 June 2024
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 1-11
Breast cancer stage and molecular subtype distribution: real-world insights from a regional oncological center in Hungary
Objective: Examining the distribution of breast cancer (BC) stage and molecular subtype among women aged below (< 45 years), within (45–65 years), and above (> 65 years) the recommended screening age range helps to understand the screening program's characteristics and contributes to enhancing the effectiveness of BC screening programs. Methods: In this retrospective study, female patients with newly diagnosed BC from 2010 to 2020 were identified. The distribution of cases in terms of TNM stages, severity classes, and subtypes was analysed according to age groups. Results: A total of 3282 women diagnosed with BC were included in the analysis. Among these cases 51.4% were detected outside the screening age group, and these were characterized by a higher TNM stage compared to those diagnosed within the screening age band. We observed significantly higher relative frequency of advanced BC in the older age group compared to both the screening age population and women younger than 45 years (14.9% vs. 8.7% and 7.7%, P < 0.001). HR−/HER2− and HER+ tumours were relatively more frequent among women under age 45 years (HR−/HER2−: 23.6%, HER2+: 20.5%) compared to those within the screening age range (HR−/HER2−: 13.4%, HER2+: 13.9%) and the older age group (HR−/HER2−: 10.4%, HER2+: 11.5%). Conclusions: The findings of our study shed light on potential areas for the improvement of BC screening programs (e.g., extending screening age group, adjusting screening frequency based on molecular subtype risk status) in Hungary and internationally, as well.
- 22 June 2024
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 1-11
Open AccessBreast cancer stage and molecular subtype distribution: real-world insights from a regional oncological center in Hungary
Objective: Examining the distribution of breast cancer (BC) stage and molecular subtype among women aged below (< 45 years), within (45–65 years), and above (> 65 years) the recommended screening age range helps to understand the screening program's characteristics and contributes to enhancing the effectiveness of BC screening programs. Methods: In this retrospective study, female patients with newly diagnosed BC from 2010 to 2020 were identified. The distribution of cases in terms of TNM stages, severity classes, and subtypes was analysed according to age groups. Results: A total of 3282 women diagnosed with BC were included in the analysis. Among these cases 51.4% were detected outside the screening age group, and these were characterized by a higher TNM stage compared to those diagnosed within the screening age band. We observed significantly higher relative frequency of advanced BC in the older age group compared to both the screening age population and women younger than 45 years (14.9% vs. 8.7% and 7.7%, P < 0.001). HR−/HER2− and HER+ tumours were relatively more frequent among women under age 45 years (HR−/HER2−: 23.6%, HER2+: 20.5%) compared to those within the screening age range (HR−/HER2−: 13.4%, HER2+: 13.9%) and the older age group (HR−/HER2−: 10.4%, HER2+: 11.5%). Conclusions: The findings of our study shed light on potential areas for the improvement of BC screening programs (e.g., extending screening age group, adjusting screening frequency based on molecular subtype risk status) in Hungary and internationally, as well.
- Open Access
- 25 April 2024
- Published by MDPI AG in Healthcare
- Vol. 12 (9) , 889
Overcoming Barriers in Hospital-Based Health Technology Assessment (HB-HTA): International Expert Panel Consensus
The purpose of this article is to investigate the common facilitators and barriers associated with the implementation of hospital-based health technology assessment (HB-HTA) across diverse hospital settings in seven countries. Through a two-round Delphi study, insights were gathered from a panel of 15 HTA specialists from France, Hungary, Italy, Kazakhstan, Poland, Switzerland, and Ukraine. Experts initially conducted a comprehensive review of the HB-HTA implementation in their respective countries, identifying the barriers and facilitators through descriptive analysis. Subsequently, panel experts ranked these identified barriers and facilitators on a seven-point Likert scale. A median agreement score ≥ 6 and interquartile range (IQR) ≤ 1 was accepted as reaching a consensus. Out of the 12 statements categorized as external and internal barriers and facilitators, the expert panel reached consensus on six statements (two barriers and four facilitators). The external barrier, which achieved consensus, was the lack of the formal recognition of the role of HB-HTA in national or regional legislations. The internal barrier reaching consensus was the limited availability of human resources dedicated to HB-HTA. This qualitative study indicates that HB-HTA still has progress to make before being formally accepted and integrated across most countries, although by building on the facilitating factors we identified there may be an opportunity for the implementation of internationally developed strategies to strengthen HB-HTA practices.
- 25 April 2024
- Published by MDPI AG in Healthcare
- Vol. 12 (9) , 889
Open AccessOvercoming Barriers in Hospital-Based Health Technology Assessment (HB-HTA): International Expert Panel Consensus
The purpose of this article is to investigate the common facilitators and barriers associated with the implementation of hospital-based health technology assessment (HB-HTA) across diverse hospital settings in seven countries. Through a two-round Delphi study, insights were gathered from a panel of 15 HTA specialists from France, Hungary, Italy, Kazakhstan, Poland, Switzerland, and Ukraine. Experts initially conducted a comprehensive review of the HB-HTA implementation in their respective countries, identifying the barriers and facilitators through descriptive analysis. Subsequently, panel experts ranked these identified barriers and facilitators on a seven-point Likert scale. A median agreement score ≥ 6 and interquartile range (IQR) ≤ 1 was accepted as reaching a consensus. Out of the 12 statements categorized as external and internal barriers and facilitators, the expert panel reached consensus on six statements (two barriers and four facilitators). The external barrier, which achieved consensus, was the lack of the formal recognition of the role of HB-HTA in national or regional legislations. The internal barrier reaching consensus was the limited availability of human resources dedicated to HB-HTA. This qualitative study indicates that HB-HTA still has progress to make before being formally accepted and integrated across most countries, although by building on the facilitating factors we identified there may be an opportunity for the implementation of internationally developed strategies to strengthen HB-HTA practices.
- Open Access
- 26 April 2023
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 11
Recommendations to overcome barriers to the use of artificial intelligence-driven evidence in health technology assessment
Background: Artificial intelligence (AI) has attracted much attention because of its enormous potential in healthcare, but uptake has been slow. There are substantial barriers that challenge health technology assessment (HTA) professionals to use AI-generated evidence for decision-making from large real-world databases (e.g., based on claims data). As part of the European Commission-funded HTx H2020 (Next Generation Health Technology Assessment) project, we aimed to put forward recommendations to support healthcare decision-makers in integrating AI into the HTA processes. The barriers, addressed by the paper, are particularly focusing on Central and Eastern European (CEE) countries, where the implementation of HTA and access to health databases lag behind Western European countries.Methods: We constructed a survey to rank the barriers to using AI for HTA purposes, completed by respondents from CEE jurisdictions with expertise in HTA. Using the results, two members of the HTx consortium from CEE developed recommendations on the most critical barriers. Then these recommendations were discussed in a workshop by a wider group of experts, including HTA and reimbursement decision-makers from both CEE countries and Western European countries, and summarized in a consensus report.Results: Recommendations have been developed to address the top 15 barriers in areas of (1) human factor-related barriers, focusing on educating HTA doers and users, establishing collaborations and best practice sharing; (2) regulatory and policy-related barriers, proposing increasing awareness and political commitment and improving the management of sensitive information for AI use; (3) data-related barriers, suggesting enhancing standardization and collaboration with data networks, managing missing and unstructured data, using analytical and statistical approaches to address bias, using quality assessment tools and quality standards, improving reporting, and developing better conditions for the use of data; and (4) technological barriers, suggesting sustainable development of AI infrastructure.Conclusion: In the field of HTA, the great potential of AI to support evidence generation and evaluation has not yet been sufficiently explored and realized. Raising awareness of the intended and unintended consequences of AI-based methods and encouraging political commitment from policymakers is necessary to upgrade the regulatory and infrastructural environment and knowledge base required to integrate AI into HTA-based decision-making processes better.
- 26 April 2023
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 11
Open AccessRecommendations to overcome barriers to the use of artificial intelligence-driven evidence in health technology assessment
Background: Artificial intelligence (AI) has attracted much attention because of its enormous potential in healthcare, but uptake has been slow. There are substantial barriers that challenge health technology assessment (HTA) professionals to use AI-generated evidence for decision-making from large real-world databases (e.g., based on claims data). As part of the European Commission-funded HTx H2020 (Next Generation Health Technology Assessment) project, we aimed to put forward recommendations to support healthcare decision-makers in integrating AI into the HTA processes. The barriers, addressed by the paper, are particularly focusing on Central and Eastern European (CEE) countries, where the implementation of HTA and access to health databases lag behind Western European countries.Methods: We constructed a survey to rank the barriers to using AI for HTA purposes, completed by respondents from CEE jurisdictions with expertise in HTA. Using the results, two members of the HTx consortium from CEE developed recommendations on the most critical barriers. Then these recommendations were discussed in a workshop by a wider group of experts, including HTA and reimbursement decision-makers from both CEE countries and Western European countries, and summarized in a consensus report.Results: Recommendations have been developed to address the top 15 barriers in areas of (1) human factor-related barriers, focusing on educating HTA doers and users, establishing collaborations and best practice sharing; (2) regulatory and policy-related barriers, proposing increasing awareness and political commitment and improving the management of sensitive information for AI use; (3) data-related barriers, suggesting enhancing standardization and collaboration with data networks, managing missing and unstructured data, using analytical and statistical approaches to address bias, using quality assessment tools and quality standards, improving reporting, and developing better conditions for the use of data; and (4) technological barriers, suggesting sustainable development of AI infrastructure.Conclusion: In the field of HTA, the great potential of AI to support evidence generation and evaluation has not yet been sufficiently explored and realized. Raising awareness of the intended and unintended consequences of AI-based methods and encouraging political commitment from policymakers is necessary to upgrade the regulatory and infrastructural environment and knowledge base required to integrate AI into HTA-based decision-making processes better.
- Open Access
- 2 March 2023
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 12 (4) , e220157
Guidance on using real-world evidence from Western Europe in Central and Eastern European health policy decision making
Aim:Real-world data and real-world evidence (RWE) are becoming more important for healthcare decision making and health technology assessment. We aimed to propose solutions to overcome barriers preventing Central and Eastern European (CEE) countries from using RWE generated in Western Europe.Materials & methods:To achieve this, following a scoping review and a webinar, the most important barriers were selected through a survey. A workshop was held with CEE experts to discuss proposed solutions.Results:Based on survey results, we selected the nine most important barriers. Multiple solutions were proposed, for example, the need for a European consensus, and building trust in using RWE.Conclusion:Through collaboration with regional stakeholders, we proposed a list of solutions to overcome barriers on transferring RWE from Western Europe to CEE countries.
- 2 March 2023
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 12 (4) , e220157
Open AccessGuidance on using real-world evidence from Western Europe in Central and Eastern European health policy decision making
Aim:Real-world data and real-world evidence (RWE) are becoming more important for healthcare decision making and health technology assessment. We aimed to propose solutions to overcome barriers preventing Central and Eastern European (CEE) countries from using RWE generated in Western Europe.Materials & methods:To achieve this, following a scoping review and a webinar, the most important barriers were selected through a survey. A workshop was held with CEE experts to discuss proposed solutions.Results:Based on survey results, we selected the nine most important barriers. Multiple solutions were proposed, for example, the need for a European consensus, and building trust in using RWE.Conclusion:Through collaboration with regional stakeholders, we proposed a list of solutions to overcome barriers on transferring RWE from Western Europe to CEE countries.